Overall Cost of DMTs Stable 2018–2020, Study Finds

Overall Cost of DMTs Stable 2018–2020, Study Finds

291495

Overall Cost of DMTs Stable 2018–2020, Study Finds

The overall cost of disease-modifying therapies for multiple sclerosis (MS) in the U.S. remained stable from 2018 to 2020, according to pharmacy and medical claims data from Prime Therapeutics’ insured members. This stabilization derived from a balance between a reduction in Copaxone (glatiramer acetate injection) use due to the arrival of its generics, and an increase in the use of Ocrevus (ocrelizumab). Generics are nearly identical versions of an original branded medication, typically sold at…

You must be logged in to read/download the full post.